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Summary 
The liver of C57BL/6 mice contains a major subset of CD4+8 - and CD4-8-  T cell receptor 
(TCR)-cx/[3 + cells expressing the polymorphic natural killer NKI.1 surface marker. Liver 
NK1. I+TCR-ot/[3 + (NK1 + T) cells require interaction with [32-microglobulin-associated, ma- 
jor histocompatibility complex class I-like molecules on hematopoietic cells for their develop- 
ment and have a TCR repertoire that is highly skewed to V[38.2, V[37, and V[32. We show 
here that congenic C57BL/6.V[3 ~ mice, which lack V[38-expressing T cells owing to a ge- 
nomic deletion at the V[3 locus, maintain ormal evels of liver NK1 + T cells owing to a dra- 
matic increase in the proportion of cells expressing V[37 and V[32 (but not other V[3s), More- 
over, in C57BL/6 congenic TCK-V[33 and -V[38.1 transgenic mice (which in theory should 
not express other V[3, owing to allelic exclusion at the TC1L-[3 locus), endogenous TCR-  
V[38.2, V[37, and V[32 (but not other V[3s) are frequently expressed on liver NKI+T cells but 
absent on lymph node T cells. Finally, when endogenous V[3 expression isprevented in TCR-  
V[~3 and V[38.1 transgenic mice (by introduction of a null allele at the C[3 locus), the develop- 
ment of liver NKI+T cells is totally abrogated. Collectively, our data indicate that liver 
NKI+T cells have a stringent requirement for expression of TCR-V[38.2, V[37, or V[32 for 
their development. 
A mature T cell subset comprising CD4+8 - and CD4-8-  double'negative (DN) TCR-oJ[3 + cells ex- 
pressing the polymorphic NKI.1 marker has been demon- 
strated to reside in thymus, bone marrow, spleen, and liver of 
appropriate mouse strains (reviewed in references 1-3). 
NK1.1 + TCR-ot/[3 + (NK1 + T) cells have a restricted usage 
of TCK-V[3 genes (mainly V[38.2, V[37, and V[32) and re- 
quire [32-microglobulin ([32m)-associated (MHC class I-like) 
molecules on hematopoietic cells for their development. 
Other characteristics ofNK1 + T cells are well studied, espe- 
cially in thymus. They have a potential to secrete large 
amounts of IL-4 and IFN-~ upon primary stimulation in 
vitro and in vivo, and freshly isolated NK1 + T cells can di- 
rectly kill CD4+8 + thymocytes via the Fas pathway. IL-7 
seems to induce a preferential expansion ofNK1 + T cells in 
normal but not in [32m-deficient mice. DN NK1 + T cells 
were originally proposed as a possible source of lymph node 
DN T cells in autoimmune Ipr/Ipr mice. Although both 
populations are absent in [~2 m- / -  mice, they seem to belong 
to different lineages, because lpr DN T cells undergo nega- 
tive selection mediated by endogenous uperantigens, 
whereas DN NK1 + T cells do not. Most recently it has 
been reported that thymic NK1 + T cells predominantly use 
an invariant ot chain, Vcx14-Ja281 (4), suggesting an inter- 
action with a restricted set ofligands. 
Since NK1 + T cells preferentially use V[38.2, V[37, and 
VI32 gene segments in normal mice, we have investigated 
whether they formally require these V[3s, by three ap- 
proaches. First, we studied congenic C57BL/6 (B6).VI3 ~ 
mice, which express the NKI.1 marker and have no V[~8 + 
T cells, owing to genomic deletion of the V[38 locus. Liver 
NK1 + T cells in these mice were present at normal evels 
and expressed either V[37 or V[32 but not other V[3s. Sec- 
ond, analysis of TCR-V[33 and -V[38.1 transgenic mice on 
a B6 background revealed that liver NK1 + T cells selec- 
tively expressing endogenous V[38.2, V[37, and V[32 (but 
not other V[3s) still can arise. Finally, we derived TCR-  
V[33 and -V[38.1 transgenic mouse strains unable to express 
endogenous V[3 chains by backcrossing them to TCR-[3 -/- 
mice that have a homozygous deletion encompassing both 
C[3 genes (5). NK1 + T cells were totally absent in the liver 
of these mice, whereas conventional T cells developed nor- 
really. Collectively, our data demonstrate a stringent TC1L- 
V[3 requirement for the development ofliver NK1 + T cells. 
Materials and Methods 
Mice. B6 mice were purchased from Harlan Olac (Bicester, 
UK). Congenic B6.V[3 amice (a kind gift of Dr. A. Livingstone, 
Basel Institute for Immunology, Basel, Switzerland) were derived 
by transferring the V[3 ~ haplotype (which has an extensive dele- 
tion at the TCK-13 locus, including V[~5, 8, 9, 11, 12, and 13 
gene segments [6]) from C57L (H-2 b, V[3 a) to B6 mice (H-2 b, 
v[3b). The B6.V[3 ~ mice used were backcrossed for 15 generations 
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to B6. TCR-V[33 (7) and -V[38.1 (8) transgenic mice on a B6 back- 
ground were kindly provided by Dr. M. Dohlsten (Pharmacia 
Biotech, Lurid, Sweden) and Dr. H. Pircher (University Hospital, 
Zurich, Switzerland). TC1K-V[33 and -V[38.1 transgenic mice lack- 
ing endogenous V[3 expression were obtained by backcrossing to
TCR-[3 - / -  mice (The Jackson Laboratory, Bar Harbor, ME), 
which are homozygous for a deletion in the TCR C[3 locus (5). 
F2 progeny were typed for expression of transgenic and/or en- 
dogenous TCIK-~ chains by staining of PBLs with appropriate 
anti-VI3 mAbs. All mice were used between 2 and 5 months of age. 
Cell Preparation. To obtain liver mononuclear cells (MNCs), the 
liver was pressed through a stainless teel mesh and suspended in
50 ml of PBS (9). After being washed once with PBS, the cells 
(including MNCs and hepatocytes) were fractionated by discon- 
tinuous (40% and 80%) Percoll gradient centrifugation for 10 min 
at 900 g. The interface was harvested, washed with 5% FCS PBS, 
and used for experiments. MNCs from lymph nodes were ob- 
tained by a standard method. 
Antibodies and Flow Cytometric Analysis. The following mAb 
conjugates were used in this study: H57-597-PE (anti-TCR-13; 
Caltag Laboratories, San Francisco, CA); GK1.5-PE (anti-CD4; 
Becton Dickinson and Co., Mountain View, CA); PK136-biotin 
(anti-NKl.1; Pharmingen, San Diego, CA). F23.1-FITC (anti- 
V[38.1-8.3), F23.2-FITC (anti-V[38.2), and 44-22-FITC (and-V[36) 
were prepared in our laboratory. Unconjugated KJ16 (anti-V[38.1/ 
8.2), TIK310 (anti-V[~7), KJ25 (anti-V[33), and B20.6.5 (anti-V[52) 
were developed with FITC-conjugated goat anti-rat IgG (Caltag 
Laboratories) or goat anti-mouse IgG and lgM (Tago, Inc., Burl- 
ingame, CA). Kat or mouse Ig was used to block free Ig sites be- 
fore addition of streptavidin Tri-color and analyzed by FACScan 
using the Lysis II program (Becton Dickinson and Co.) To detect 
co-expression f [3 T (V[33) and [3 E (V[38) on liver CD4+NK1 + T 
cells of TCK-V[33 transgenic mice, four-color flow cytometric 
analysis was performed. Unconjugated KJ25 (anti-[3T) was devel- 
oped with PE-conjugated goat F(ab')2 anti-mouse IgG (Caltag 
Laboratories), mouse Ig was used to block, and F23.1-FITC (anti- 
[3E), PK136-biotin, and GK1.5-1Ked613 (GIBCO B1KL [Life 
Technologies, Inc.], Gaithersburg, MD) were added. The biotin- 
ylated reagent was revealed with streptavidin-aUophycocyanin 
(Caltag Laboratories). Samples were analyzed with a FACStar Plus 
equipped with the Lysis II program (Becton Dickinson and Co.). 
Results and Discussion 
We first compared the proportion of  total NK1 + T cells, 
CD4+NK1 + T cells, and TCR-V[3 usage among CD4 + 
NK1 + T cells in the livers of  normal B6 mice and congenic 
B6.V[3 a mice (Fig. 1 and Table 1). As expected from our 
previous study (9), liver CD4+NK1 + T cells of  control B6 
mice express V[38 (69.3 + 3.4%), V~7 (14.4 -+ 1.7%), and 
V[32(8.1 + 0.4%) at much higher levels when compared 
with lymph node CD4 + T cells (22.1 + 2.5%, 1.8 + 0.3%, 
and 6.5 + 0.8%, respectively). Other V[3s were virtually 
absent in liver CD4+NK1 + T cells (reference 9; data not 
shown). In congenic B6.V[3 a mice, a normal frequency of  
liver NK1 + T cells and CD4+NK1 + T cells was observed 
as compared with that in B6 mice, despite the total absence 
of  V[38 + cells (<1%). Instead, B6.v[3a liver CD4+NK1 + T 
cells use V[37 (46.2 -+ 5.7%) and V[32 (47.1 -+ 3.6%) much 
more frequently than cells from normal mice; however, 
they do not express V[36, V[33, V[34, and V[310, which are 
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Figure 1. (A) Proportion of total and CD4+NK1 + T cells in liver of 
B6 and B6.VI3 ~ mice. Liver MNCs were stained with H57-597-PE (anti- 
TCR-I3) or GK1.5-PE (anti-CD4) and PK136-biotin (anti-NKl.1) plus 
streptavidin Tri-color. One representative experiment is shown. The 
numbers correspond tothe population of total or CD4+NK1 + T cells in 
each strain. (B) V[3 expression of liver CD4+NK1 + T cells in B6 and 
B6.V[3 ~ mice. Liver MNCs were stained with the indicated FITC-conju- 
gated anti-VI3 mAbs followed by GK1.5-PE and PK136-hiotin plus 
streptavidin Tri-color. Histograms are gated on CD4+NK1 § T cells. 
not deleted in B6.VI3 a mice (data not shown). Lymph node 
CD4 + T cells in B6.V[3 ~ mice used V137 (3.0 -+ 0.7%) and 
V132 (14.0 + 3.6%) at moderately higher levels than in B6 
mice, presumably owing to the absence of  several V[3s in 
this haplotype (6). Thus, liver CD4+NK1 § T cells seem to 
require TCR,-VI38.2, VI37, or VI32 for development, since 
other VI3s cannot substitute for V138.2 in B6.VI3 ~ mice. 
To further confirm the stringency of  the VI3 requirement 
for development off icer NK1 + T cells, we also investigated 
NK1 + T cells in the liver of  TCR-VI33 and -V138.1 trans- 
genic mice (Fig. 2 A and Table 2). As expected, most lymph 
node CD4 + T cells ofV[33 transgenic mice (95.4 -+ 0.9%) 
expressed transgenic V133 03T), whereas endogenous Vt3s 
(13E) such as V138, V[37, V[32, and V[36 were very rare. In 
liver, the proportions of  both total NK1 § T cells (7.8 + 
0.9%) and CD4+NK1 + T cells (4.6 -+ 0.6%) were reduced 
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Table 1. TCR-V[3 Usage among Liver CD4+NK1 + T Cells 
and Lymph Node CD4 + T cells of B6 and B6. V~8 aMice 
Liver CD4+NK1 + LN CD4 + 
V[3s B6 B6.V[3 9 B6 B6.V[3 ~ 
% % % % 
8 69.3 + 3.4 0.6 + 0.2 22.1 + 2.5 0.7 +- 0.2 
7 14.4 + 1.7 46.2 + 5.7 1.8 -+ 0.3 3.0 + 0.7 
2 8.1 --+ 0.4 47.1 + 3.6 6.5 + 0.8 14.0 + 0.5 
6 1.1 + 0.3 1.8 + 0.4 8.3 +- 0.4 11.5 --- 0.5 
Four B6 or B6.V[3 ~ mice aged 4 mo were analyzed individually. Cells 
were stained with the indicated anti-V[3 mAbs and gated as described in 
Fig. 1. Data are expressed as mean • SD. Proportions of total liver 
NK1 + cells and CD4+NK1 + cells were 23.1% + 2.1% and 14.7 + 
2.5% in B6 mice, and 19.9 --. 4.7% and 13.9 +- 3.8% in B6.V[3 a mice, 
respectively. 
about threefold as compared with normal age-matched B6 
mice (23.1 + 2.1% and 14.7 -+ 2.5%). The majority of  liver 
CD4+NK1 + T cells expressed [~v (76.9 +-+- 2.7%), although 
the intensity of staining was approximately fivefold lower than 
that of  lymph node CD4 + T cells (Fig. 2 B). Surprisingly, 
liver CD4+NK1 + T cells from the transgenic mice also ex- 
pressed endogenous V[38 (72.1 + 4.3%), V[37 (11.2 + 2.9%), 
or V[32 (3.2 --- 0.9%) at similar frequencies as in nontrans-  
genic controls (Fig. 2 B and Table 2). Coexpression of  [3 T 
(V[33) and [~E (V[38) on a majority o f  liver CD4+NK1 + T 
cells was directly conf irmed by four-color flow microf luo- 
rometry (Fig. 2 C). Other  [3rs, such as VI36, were not  seen 
in liver CD4+NK1 + T cells ofTC1K-V[33 transgenic mice. 
The results obtained in TC1K-V[33 transgenic mice were 
basically conf irmed in TC1K-V[38.1 transgenic mice (Fig. 2 
and Table 2). In the latter mice, most lymph node CD4 § 
T cells expressed [3T (96.3 --+ 1.8%) but  not [3E, whereas 
liver CD4 + NK1 + T cells expressed 13 E at levels close to 
those of  normal B6 mice (V[38.2, 47.6 + 2.3%; V[37, 19.5 + 
2.6%; V[~2, 7.5 + 1.7%). Analysis o f  [3 T expression in liver 
CD4+NK1 + T cells was complicated by the fact that KJ16 
mAb,  which was used for staining, recognizes both V[38.1 
(~T) and V[38.2 ([3E). 
The simultaneous expression of  [3 T and ~E on a high 
proport ion of  liver CD4+NK1 + T cells is unexpected in 
view of  the fact that inhibi t ion of  endogenous rearrange- 
ment  at the TCIK-[3 locus via allelic exclusion is usually ef- 
ficient in TCR transgenic mice (10). However,  there are 
several reported transgenic models where [3t genes are rear- 
ranged and expressed, particularly under  condit ions of  low 
levels of  transgene xpression (11) and strong negative se- 
lection (12). In the case of  liver NK1 + T lineage cells, the 
expression of  two 13 chains seems rather to reflect a strong 
positive selection for rare cells that have endogenously re- 
arranged [3 chains with "permissive" V[3 domains. Indeed, 
[3E expression on liver NK1 + T cells in both V[33- and 
V[38.1-transgenic mice was restricted to V[38.2, V[37, and 
V~2. Moreover,  the relative proport ion of  transgenic 
NK1 + T cells expressing these endogenous V[3 domains was 
virtually identical to what is found in normal  liver. Lack of  
allelic exclusion at the TC1L-[3 locus is not  a general prop-  
erty of  liver NK1 + T cells, since no cells expressing two 
V[3 domains could be detected in normal mouse liver (data 
not  shown). 
To  formally test whether NK1 + T cells are able to de- 
velop in the absence of appropriate V[3 expression, we crossed 
TCI<-V[33 and -V[38.1 transgenic mice with TCP,.-[3 - / -  
mice that have a homozygous deletion encompassing both 
CI3 domains (5). TC1L transgenic F1 mice were then back- 
crossed to TCP,-[3 - / -  mice, and the F2 progeny were 
typed for expression of  the TCR transgenes as well as for 
endogenous V[3 expression. As shown in Fig. 3 and Table 
3, no NK1 + T cells were detectable in the liver of  TCR-  
V[33 and -V138.1 transgenic TC1K-[3 - / -  mice, whereas (as 
expected from Fig. 2) liver NK1 + T cells expressing en-  
Table 2. Predominant Usage of Endogenous V~s among Liver CD4+ NK1 + T Cells of TCR-~-Chain Transgenic Mice 
Liver CD4+NK1 § LN CD4 + 
V[3s B6 V[33 T V[38.1T B6 V[33T V[38.1T 
~T 
% % % % % % 
3, 8.1-8.2 - -  76.9 _+ 2.7 75.3 + 8.3 - -  95.4 - 0.9 96.3 + 1.8 
8.1-8.3 69.8 + 0.9 72.1 + 4.3 - -  21.4 + 1.5 3.1 + 0.5 - -  
8.2 55.0 + 2.4 ND 47.6 + 2.3 10.4 + 0.3 ND 3.6 + 0.9 
7 18.3 + 1.3 11.2 + 2.9 19.5 + 2.6 1.7 + 0.2 0.3 + 0.1 0.9 + 0.3 
2 8.6 _+ 0.4 3.2 -+ 0.9 7.5 -+ 1.7 6.1 + 0.3 0.2 + 0.1 1.2 _+ 0.2 
6 1.3 +- 0.1 1.0 + 0.2 1.1 __+ 0.3 8.6 + 0.3 0.4 + 0.2 1.7 + 0.5 
Three to four mice in each group were individually analyzed. Liver MNC and lymph node cells were stained with indicated anti-V [3 mAbs and 
gated as Fig. 2. Data are expressed as mean + SD. Proportions of total iver NK1 + cells and CD4+NK1 + cells were 23.1 + 2.1% and 14.7 + 2.3% in 
B6 mice, 7.8 + 0.9% and 4.6 + 0.6% in V[~3 transgenic mice, and 8.1 -+ 0.7% and 5.2 -+ 0.6% in V[38.1 transgenic mice. ND, not done. 
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dogenous V~ domains were frequent in TCR transgenic 
TC Ik  13 +~- l ittermate controls. In contrast, the develop-  
ment  o f  normal (NK1,1=) T cells in l iver and lymph nodes 
o f  TCR-V~3-  or -V[~8.1-transgenic mice was not  affected 
A 
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8.2% 7.8% 
d= e 
4.7% 5.3% 
B 
NKI.1 
L iver  V~3T V~8.1T  
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/ \ 1!~. (vp8.~/ 
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/h i~ 99.2~ ,~ ~ 98.3~ 
3.0o/0 ~ 2"7% ~ E (vl~8) 6/~, 8.2I 
Fluorescence Intensity (log) 
C Liver LN 
V~3T V~ 8.1T Littermate 
c, 'h 
L) 
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68.8  10.769.0 13.5 61.2 29.C 
o 
87.4 2.2 71.0 1.8 <1 < 
NKI.1 
F igure  3. Absence ofNK1 + T cells in the liver of V[33- and V[38.1- 
transgenic mice lacking endogenous V[3 expression. Liver MNCs from 
TCR transgenic or littermate control mice with ([3E +/-) or without (13r -/-) 
endogenous Vt3 expression were stained with mAbs against TCP--I~ and 
NK1.1. The proportion of cells in each quadrant is indicated. 
by the presence or absence o f  endogenous V[3 expression 
(Fig. 3; data not shown). These data formally establish that 
l iver NK1 + T cells fail to develop unless they are able to 
express permissive V~ domains. 
In conclusion, we show here that the development  o f  
NK1 + T cells in mouse l iver is strictly dependent upon the 
util ization o f  a highly restricted susbset o f  V[3 domains, in- 
c luding V[38,2, V[37, and V{32. In contrast, most V[3- 
restricted responses o f  peripheral CD4 + or CD8 + T cells to 
convent ional  protein antigens in v ivo are more plastic, 
since in the absence of  a dominant  epitope, T cells express- 
ing other V[3 domains specific for previously cryptic or sub- 
dominant  epitopes appear (13). By analogy with these het-  
erogeneous protein antigen responses, it seems probable 
that the physiological l igand responsible for the develop-  
ment  (and/or  expansion) o f  l iver NK1 + T cells in vivo is 
highly monomorph ic .  In this regard, it has recently been 
Tab le  3.  Endogenous Vfl Expression Is Required for NK I  § T 
Cell Development in the Liver of TCR- Vfl3 and - VflS. 1 Transgenic 
Mice 
17.3 59.2 94.8 3.3 
.. 20.5 "-.. 1 .( 
F igure  2. (/t) Proportion of total and CD4+NK1 + T cells in liver of 
V[~3- and V~8.1-transgenic mice. Liver MNCs were stained as in Fig. 1 
A. (/3) Transgenic ([3T) and endogenous (BE) VI3 expression on liver 
CD4+NK1 + T cells and lymph node CD4 + cells. V~ histograms were 
gated on CD4+NK1.1 + (liver) or CD4 + (lymph node) cells. (C) Coex- 
pression of transgenic (V[33) and endogenous (V[38) TCR.-~ chains on 
hver CD4+NKI.1 § cells from TCP,-VI33-transgenic mice. Four-color 
staining was performed with mAbs against CD4, NKI.1, V~3, and V~8. 
Cytograms are gated on CD4+NKI.1 + cells in liver or CD4+NKI.1 -
cells in lymph node. 
Mouse Endogenous VI3 TCR43 + CD4 + V[38.2 + 
strain expression NK1 + NK 1 + in CD4 
% % % 
V[33T + 11.3, 12.3 3.5, 3.2 16.6, 11.9 
-- 2.2,  2 .2 0.4,  0 .4 0.1,  0.2 
V~8.1T + 12.5 + 1.0 3.9 + 0.7 13.6 + 2.7 
- 1.9 + 0.5 0.3 + 0.1 0.3 + 0.1 
Litter- 
mate + 28.7 - 2.9 12.2 _.+ 2.4 30.7 + 2.2 
- <1  <1 <1 
Two to four mice in each group were analyzed individually. Liver 
MNCs were stained as in Fig. 2. Data are expressed as mean + SD un- 
less otherwise indicated (individual mice). Proportions of TCIq.- 
[3+NK1 + cells and CD4+NK1 + cells were estimated in 8220- cells. 
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shown that most thymic NK1 + T cells bear a highly con- 
served TCR-ot  chain consisting of  VoL14-Jot281 rearrange- 
ments with fitde (or no) junctional diversity (4). Similar 
Vo~14-Jot281 rearrangements, which are believed to occur 
extrathymically (14), are frequent in other tissues, such as 
bone marrow or liver (15). Interestingly, DN TCR-a / [3  + T 
cells using a conserved Vo~24-JaQ rearrangement that is 
highly homologous to the mouse VoL14-J(x281 sequence 
are expanded in the peripheral blood of  many normal indi- 
viduals (4, 16), suggesting that a related (or identical) ligand 
is responsible for the selection of  a distinct subset of  T cells 
in both mouse and humans, The precise nature of  the 
ligand recognized by NK1 + T cells remains controversial. 
Since NK1 + T cells are present in TAP-l--deficient mice 
(17) but fail to develop in [32m-deficient mice (1-3), it is 
likely that the ligand should consist (at least in part) of  a 
TAP- independent [32m-associated molecule such as thymus 
leukemia antigen (18) or CD1 (19). Indeed, NK1 + T cells 
and hybridomas have recently been shown to recognize fi- 
broblast stimulator cells infected with a vaccinia virus con- 
struct expressing the mouse CD1 gene (20). Moreover, cer- 
tain constituents of  mycobacteria, such as lipoglycans and 
mycotic acid, can be recognized by some human DN TCR-  
od[3 + cell lines in association with CDlb  (21, 22). Whether  
mouse NK1 + T cells can also recognize CDl-associated my- 
cobacterial antigens remains, however, to be determined. 
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